Wrap Text
QLE enters into MOU with European Nuclear Technology Company for Advanced Nuclear Fuel Supply Collaboration
ASP ISOTOPES INC.
(Incorporated in the State of Delaware,
United States of America)
(Delaware file number 6228898)
Ticker Symbol: NASDAQ: ASPI
ISIN: US00218A1051
LEI: 6488WHV94BZ496OZ3219
JSE Share Code: ISO
("ASPI" or "the Company")
QUANTUM LEAP ENERGY ENTERS INTO MEMORANDUM OF UNDERSTANDING WITH EUROPEAN
NUCLEAR TECHNOLOGY COMPANY FOR ADVANCED NUCLEAR FUEL SUPPLY COLLABORATION
MOU establishes framework for collaboration with the goal to supply HALEU to European advanced
reactor developer, beginning 2028
DALLAS, May 11, 2026 -- ASP Isotopes Inc. (NASDAQ: ASPI) ("ASPI") today announced that Quantum
Leap Energy LLC ("we," "QLE" or the "Company"), a wholly-owned subsidiary of ASPI dedicated to
advancing innovative technologies and processes across critical segments of the fission and fusion nuclear
fuel cycle, has entered into a non-binding Memorandum of Understanding (MOU) with a European nuclear
technology company specializing in advanced nuclear reactor development and other next-generation
nuclear energy solutions.
"Securing reliable HALEU supply is one of the most critical challenges facing the advanced nuclear industry
today. This MOU is a meaningful step in QLE's mission to build enrichment capabilities that serve both U.S.
and global markets. We look forward to working with a partner that shares our conviction that next-
generation nuclear energy is essential to a clean and secure energy future," said Dr. Ryno Pretorius, Chief
Executive Officer of Quantum Leap Energy.
Under the terms of the MOU, the parties will conduct a technical and economic assessment to determine
the viability of a long-term collaboration for the supply of high assay low enriched uranium (HALEU) with
uranium-235 content of greater than 10%. The MOU outlines a potential framework where the European
partner would agree to provide uranium feedstocks to QLE's planned conversion and enrichment facilities,
and QLE would agree to enrich such feedstocks to produce HALEU, including potential deconversion, for
delivery to the partner company.
The term of the MOU extends through December 31, 2030, subject to early termination by either party. The
scope of the activities contemplated by the MOU includes the parties' assessment of operational
requirements, production scalability for conversion and enrichment, and associated costs and commercial
models. The MOU also includes non-binding estimates of quantities of HALEU, with potential deliveries
beginning in 2028 and quantities scaling up through 2036, based on the partner's reactor development
timeline and anticipated fuel requirements.
The MOU comes amid growing global urgency to establish diverse and reliable HALEU production
capabilities. With increasing demand from next-generation reactor developers worldwide and evolving
geopolitical dynamics affecting nuclear fuel supply chains, domestic U.S. enrichment capacity capable of
serving both domestic and international customers is expected to be critical for the advancement of
advanced nuclear energy systems.
About Quantum Leap Energy
Quantum Leap Energy is a development stage nuclear fuels company dedicated to advancing innovative
technologies and processes across critical segments of the nuclear fuel cycle. The Company focuses on
both front-end activities, including uranium conversion, enrichment of uranium-235 for nuclear fuel
production (HALEU, LEU+ and LEU), and isotopic separation of lithium-6 and lithium-7, as well as back-
end radioactive waste treatment technologies. Through exclusive global rights to proprietary Aerodynamic
Separation Process (ASP) and laser-based Quantum Enrichment (QE) technologies, Quantum Leap
Energy aims to address perceived gaps in the nuclear fuel supply chain for advanced nuclear reactors,
small modular reactors, and fusion systems. The Company has established strategic partnerships or
commercial initiatives and relationships with industry leaders including TerraPower, Fermi America, and the
South Africa Nuclear Energy Corporation (Necsa) to accelerate the commercialization of critical isotopes
essential for next-generation nuclear energy systems. For additional information, please visit:
https://www.qleapenergy.com/.
About ASP Isotopes Inc.
ASP Isotopes is an advanced materials company dedicated to the development of a differentiated isotope
enrichment platform to strengthen global supply chain access to critical materials used in nuclear medicine,
next-generation semiconductors, and nuclear energy. The Company's proprietary technologies, the
Aerodynamic Separation Process ("ASP technology") and Quantum Enrichment ("QE technology"), are
designed to enable the production of isotopes for a range of industrial and advanced technology
applications. ASP Isotopes operates isotope enrichment facilities in Pretoria, South Africa, focused on the
enrichment of low atomic mass elements, or light isotopes. For more information, please
visit www.aspisotopes.com.
Forward-Looking Statements
Statements contained herein relating to future plans, results, performance, expectations, achievements and
the like are considered "forward-looking statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include, but are not limited to, the planned
collaboration with a European nuclear technology company regarding QLE's planned uranium conversion,
enrichment of uranium-235 for nuclear fuel production, and uranium deconversion services, the expected
need or desire for HALEU by third parties, projections about the future nuclear fuel cycle for advanced
nuclear reactors and fusion systems, the commencement of research, development and production
activities, the future of the company's enrichment technologies as applied to uranium enrichment, QLE's
anticipated growth strategies and anticipated trends in QLE's business, statements relating to QLE's
strategic partnerships or commercial initiatives and relationships with international partners, statements
related to the anticipated benefits to QLE and the collaboration resulting from the MOU discussed herein,
and statements we make regarding expected operating results, such as future revenues and prospects
from the potential commercialization of isotopes, future performance under contracts, and our strategies for
product development, engaging with potential customers, market position, and financial results. These
forward-looking statements involve known and unknown risks, uncertainties, and other factors, many of
which may be beyond QLE's or ASPI's control, that may cause actual results to differ materially from any
future results, performance or achievements expressed or implied by any forward-looking statements.
Therefore, you should not rely on any of these forward-looking statements. There are many important
factors that could cause QLE's actual results and financial condition to differ materially from those indicated
in the forward-looking statements, including, but not limited to: the potential impact of laws or government
regulations or policies in South Africa, the United Kingdom or elsewhere; the outcomes of various strategies
and projects undertaken by the Company, including the Company's initiative to commence enrichment of
uranium in South Africa and the Company's discussions with nuclear regulators in South Africa and the
United Kingdom; whether we succeed in obtaining permissions and regulatory approvals required to test
and develop enrichment technologies on uranium in South Africa, the United Kingdom or elsewhere;
whether a market for HALEU is established; technological changes that could render our enrichment
technologies uncompetitive or obsolete; our future capital requirements and sources and uses of cash; our
ability to obtain funding for our operations and future growth; our reliance on the efforts of third parties; our
ability to obtain permissions and regulatory approvals for the production and sale of enriched uranium; the
financial terms of any current and future commercial arrangements; our ability to complete certain
transactions and realize anticipated benefits from acquisitions and contracts; dependence on our
intellectual property (IP) rights and certain IP rights of third parties; and the competitive nature of our
industry. All forward-looking statements speak only as of the date hereof. QLE and ASPI undertake no
obligation to revise or update any forward-looking statements except as may be required by applicable law.
QLE Contact
QLE@icrinc.com
ASPI Contact
IR@ASPIsotopes.com
The Company has a primary listing on the Nasdaq and a secondary listing on the Main Board of the JSE.
11 May 2026
Sponsor
Valeo Capital Proprietary Limited
Date: 11-05-2026 01:30:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
